Trial reportScientific reports2025
Inulin supplementation improves some inflammatory indices, clinical outcomes, and quality of life in rheumatoid arthritis patients.
Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Gut-bone axis in rheumatoid arthritis: microbiota-driven barrier dysfunction, immune crosstalk, and therapeutic strategies.Antonie van Leeuwenhoek · 2026Review
- The Role of Microbiome and Diet on Disease Activity and Immune-Inflammatory Status in Rheumatoid Arthritis.Nutrients · 2026Review
- The Oral-Gut-Immune-Nutrition Axis in Rheumatoid Arthritis: Molecular Mechanisms and Therapeutic Implications.International journal of molecular sciences · 2026Review
- Gut microbiota dysbiosis in rheumatoid arthritis: mechanisms linking intestinal barrier dysfunction to synovial inflammation.Frontiers in immunology · 2026Review
- Gut dysbiosis in difficult-to-treat rheumatoid arthritis: hypothesized microbial endotypes, persistent inflammation, and pharmacological treatment resistance.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a multifactorial autoimmune disease that causes joint dysfunction and is associated with changes in serum levels of some biomarkers. The present study investigated the effect of inulin supplementation on pain intensity, clinical outcomes, and quality of life in patients with RA.In a randomized, triple-blind, parallel clinical trial, 60 patients over 18 years of age with RA were randomly assigned to receive either 10 g of inulin or maltodextrin per day for 8 weeks. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels were assessed using biochemical kits at the beginning and end of the study. Clinical outcomes were also evaluated, including morning stiffness and pain intensity measured by the Visual Analog Scale (VAS), hand grip measured by a sphygmomanometer (Seca), disease activity assessed using the Disease Activity Score 28 (DAS-28), and overall quality of life determined by the Health Assessment Questionnaire (HAQ).The number of swollen joints, tender joints, pain intensity, and DAS-28 significantly decreased in both groups. However, hand grip, morning stiffness, ESR, CRP, and HAQ improved significantly only in the intervention group. After the intervention, in the intervention group compared to the control group, serum CRP levels significantly decreased (P = 0.02), while serum ESR levels showed no significant reduction (P = 0.45). The number of tender joints (P = 0.002), the number of swollen joints (P = 0.04), DAS-28, HAQ, morning stiffness, and hand grip strength (P = 0.02) significantly improved, but pain intensity did not change (P = 0.11).Inulin appears to benefit inflammatory status, disease activity, and clinical outcomes in patients with rheumatoid arthritis. Incorporating it into their treatment protocol could be valuable for managing their condition.Trial registration: Our study was approved in the Iranian Registry of Clinical Trials ( www.irct.ir ) on 10/5/2023, with the registration number IRCT20230506058098N1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.